Information about Flavoxate
Liver safety of Flavoxate
Flavoxate has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.
Mechanism of action of Flavoxate
Flavoxate (flay vox' ate) is a synthetic quaternary ammonium anticholinergic which inhibits the muscarinic actions of acetylcholine on autonomic nerve endings, decreasing the smooth muscle tone of bladder and gastrointestinal tract. Flavoxate has broad activity against muscarinic acetylcholine receptors, but its highly polar quaternary ammonium group makes it less likely to cross lipid membranes such as the blood brain barrier, which is believed to decrease the potential for central nervous system effects. Flavoxate increases bladder capacity and decreases urinary frequency and urgency.
FDA approval information for Flavoxate
Flavoxate was approved for use in the United States in 1970 and continues to be used to treat the symptoms of cystitis and overactive bladder syndrome. Flavoxate is available in tablets of 100 mg in several generic forms and previously under the brand name Urispas.
Dosage and administration for Flavoxate
The typically recommended oral dose in adults is 100 to 200 mg three or four times daily.
Side effects of Flavoxate
Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, urinary retention, impotence, tachycardia and palpitations, anxiety, restlessness and in some instances agitation and delusions. anticholinergic agents can precipitate acute narrow angle glaucoma and acute urinary retention.
- Overactive bladder syndrome agents - darifenacin, fesoterodine, flavoxate, hyoscyamine, mirabegron, oxybutynin, solifenacin, tolterodine, trospium